BioCryst to Report Fourth Quarter 2024 Financial Results on February 24
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2024 financial ...
KBC Group NV Buys 4,537 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
KBC Group NV grew its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 80.1% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 10,198 shares ...
BioCryst to present new ORLADEYO results from APeX-P pediatric trial
Pharmaceuticals announced that the company will present five abstracts featuring new clinical and real-world outcomes with ...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of ...
Bullish BioCryst Pharmaceuticals Insiders Loaded Up On US$1.05m Of Stock
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying, like in the case of BioCryst Pharmaceuticals, Inc. ( NASDAQ:BCRX ), it sends a ...
ETF Daily News23d
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Short Interest Update
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) was the recipient of a significant decline in short interest during the month of December.As of December 31st, there was short ...
JMP Securities maintains BioCryst stock with $18 target
JMP Securities reiterated its Market Outperform rating on BioCryst Pharmaceuticals (NASDAQ:BCRX) with a consistent price target of $18.00. The firm's analysis is based on the performance and market ...